Back to Search Start Over

Cutaneous side effects during therapy with Erlotinib: Case report

Authors :
Jovičić Sanja
Gajanin Vesna
Umičević-Šipka Sanja
Source :
Scripta Medica, Vol 52, Iss 4, Pp 317-320 (2021)
Publication Year :
2021
Publisher :
Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine, 2021.

Abstract

Erlotinib is an antineoplastic drug used in the treatment of non-small cell lung cancer and pancreatic cancer. It is a potent, selective inhibitor of tyrosine kinase, a receptor for epidermal growth factor receptor (EGFR). Cutaneous side effects such as acneiform eruption, xerosis, telangiectasia, hair and nail changes are common. A case of a 70-year-old patient who developed unusual cutaneous side effects after 6 years of treatment with erlotinib was presented.

Details

Language :
English, Serbian
ISSN :
24903329 and 23037954
Volume :
52
Issue :
4
Database :
Directory of Open Access Journals
Journal :
Scripta Medica
Publication Type :
Academic Journal
Accession number :
edsdoj.9b5a4e0595e84b678f18bba4cfecab61
Document Type :
article
Full Text :
https://doi.org/10.5937/scriptamed52-35385